Literature DB >> 20512116

Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression.

Irene Tveiterås Øvestad1, Einar Gudlaugsson, Ivar Skaland, Anais Malpica, Arnold-Jan Kruse, Emiel A M Janssen, Jan P A Baak.   

Abstract

Fifteen to thirty percent of cases with histologically confirmed CIN2-3 in cervical biopsies regress spontaneously (ie, show CIN1 or less in the follow-up cervical cone). The balance between immune-reactive cells from the host and high-risk human papillomavirus (hrHPV) genotypes may provide a biological explanation for this phenomenon. We retrospectively studied 55 cases of CIN2-3 in a cervical biopsy with subsequent cervical cone to assess whether hrHPV genotypes (by AMPLICOR and Linear Array tests) CD4, CD8, CD25, CD138 and Foxp3 cells (by quantitative immunohistochemistry) in the cervical biopsies can predict regression (defined as CIN1 or less in the follow-up cone biopsy). Eighteen percent of the CIN2-3 cases regressed (median biopsy-cervical cone time interval: 12.0 weeks, range: 5.0-34.1 weeks). HPV-16 correlated with low CD8+ and high CD25+. None of the regressing CIN2-3 lesions contained HPV-16. The regressing CIN2-3 lesions had lower numbers of stromal CD138+ and higher numbers of stromal CD8+cells; higher stromal and intra-epithelial ratios of CD4+/CD25+ cells; higher ratios of CD8+/CD25+ cells and lower ratios of CD8+/CD4+, CD138+/Foxp3+ and CD25+/Foxp3+ cells in the stroma. With multivariate survival analysis, stromal CD8+ cell numbers, CD4+/CD25+ cell ratios and CD138+ cell numbers are found to be independent regression predictors. In conclusion, in non-HPV-16 CIN2-3 lesions, assessing stromal immune cells can be a useful prognostic indicator of regression or persistence.

Entities:  

Mesh:

Year:  2010        PMID: 20512116     DOI: 10.1038/modpathol.2010.109

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  26 in total

Review 1.  Determination of malignant potential of cervical intraepithelial neoplasia.

Authors:  E Kudela; V Holubekova; A Farkasova; J Danko
Journal:  Tumour Biol       Date:  2015-12-22

2.  Immune Modulation and Treatment of Human Papilloma Virus-Related Warts with Energetics of Living Systems Acupuncture.

Authors:  Rom Brustin; Martine Toledano; Tal Geffen; Raia Goona; Malka Hochberg; Bilha Kreisberg; Sari Murad; Jacob Pitcovski
Journal:  Med Acupunct       Date:  2017-06-01

3.  Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Authors:  Qinghua Feng; Huafeng Wei; Janice Morihara; Joshua Stern; Mujun Yu; Nancy Kiviat; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Gynecol Oncol       Date:  2012-07-22       Impact factor: 5.482

4.  Cytokine profile in cervical mucosa of Japanese patients with cervical intraepithelial neoplasia.

Authors:  Takashi Iwata; Takuma Fujii; Kenji Morii; Miyuki Saito; Juri Sugiyama; Hiroshi Nishio; Tohru Morisada; Kyoko Tanaka; Tomonori Yaguchi; Yutaka Kawakami; Daisuke Aoki
Journal:  Int J Clin Oncol       Date:  2014-03-01       Impact factor: 3.402

5.  Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.

Authors:  Min Dai; Huafeng Wei; Yuen Yee Yip; Qinghua Feng; Kecheng He; Viorica Popov; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  J Immunother       Date:  2013-05       Impact factor: 4.456

Review 6.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

7.  Lm-LLO-Based Immunotherapies and HPV-Associated Disease.

Authors:  Anu Wallecha; Chris French; Robert Petit; Reshma Singh; Ashok Amin; John Rothman
Journal:  J Oncol       Date:  2012-02-02       Impact factor: 4.375

8.  ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer.

Authors:  Tatiana Galicia-Carmona; Eder Arango-Bravo; Juan A Serrano-Olvera; Celia Flores-de La Torre; Ivan Cruz-Esquivel; Ricardo Villalobos-Valencia; Andrés Morán-Mendoza; Denisse Castro-Eguiluz; Lucely Cetina-Pérez
Journal:  Hum Vaccin Immunother       Date:  2021-04-01       Impact factor: 3.452

9.  Immunotherapy of human papilloma virus induced disease.

Authors:  Sjoerd H van der Burg
Journal:  Open Virol J       Date:  2012-12-28

10.  Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study.

Authors:  Ane Cecilie Munk; Irene Tveiterås Ovestad; Einar Gudlaugsson; Kjell Løvslett; Bent Fiane; Bianca van Diermen-Hidle; Arnold-Jan Kruse; Ivar Skaland; Emiel Am Janssen; Jan Pa Baak
Journal:  Infect Agent Cancer       Date:  2012-11-05       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.